Adelphi Trust Co Makes New Investment in AbbVie Inc. $ABBV

Key Points

• Adelphi Trust Co bought a new stake of 9,274 shares in AbbVie (about $2.12M), making the stock 1.7% of its holdings and its 16th-largest position.
• AbbVie beat expectations with Q results of $2.71 EPS vs. $2.65 est. and $16.62B revenue vs. $16.39B est., and set FY2026 guidance of $14.37–$14.57 EPS; analysts’ consensus rating is a Moderate Buy with a $253 target.
• The company declared a quarterly dividend of $1.73 per share (annualized $6.92, yield 3.3%, ex-dividend Apr 15), while several insiders have recently sold sizable blocks of stock.

Adelphi Trust Co bought a new stake in shares of AbbVie Inc. (NYSE:ABBV - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 9,274 shares of the company's stock, valued at approximately $2,119,000. AbbVie comprises 1.7% of Adelphi Trust Co's holdings, making the stock its 16th biggest position.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Ellenbecker Investment Group boosted its stake in shares of AbbVie by 0.8% during the 3rd quarter. Ellenbecker Investment Group now owns 5,334 shares of the company's stock valued at $1,235,000 after buying an additional 44 shares during the last quarter. Security National Bank of Sioux City Iowa IA lifted its stake in AbbVie by 0.3% during the third quarter. Security National Bank of Sioux City Iowa IA now owns 15,382 shares of the company's stock worth $3,562,000 after purchasing an additional 45 shares during the last quarter. Matthew Goff Investment Advisor LLC lifted its stake in AbbVie by 0.3% during the third quarter. Matthew Goff Investment Advisor LLC now owns 17,561 shares of the company's stock worth $4,066,000 after purchasing an additional 45 shares during the last quarter. Centennial Wealth Advisory LLC lifted its stake in AbbVie by 2.2% during the third quarter. Centennial Wealth Advisory LLC now owns 2,089 shares of the company's stock worth $484,000 after purchasing an additional 45 shares during the last quarter. Finally, Willner & Heller LLC lifted its stake in AbbVie by 0.6% during the third quarter. Willner & Heller LLC now owns 7,596 shares of the company's stock worth $1,759,000 after purchasing an additional 46 shares during the last quarter. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

AbbVie Stock Performance

Shares of ABBV opened at $208.58 on Thursday. The firm has a market capitalization of $368.80 billion, a price-to-earnings ratio of 88.38, a price-to-earnings-growth ratio of 0.75 and a beta of 0.38. AbbVie Inc. has a one year low of $168.54 and a one year high of $244.81. The stock's fifty day moving average is $219.49 and its 200-day moving average is $223.78.

AbbVie (NYSE:ABBV - Get Free Report) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating analysts' consensus estimates of $2.65 by $0.06. The company had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The company's quarterly revenue was up 10.0% compared to the same quarter last year. During the same period last year, the company earned $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Analysts forecast that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 annualized dividend and a yield of 3.3%. AbbVie's dividend payout ratio (DPR) is currently 293.22%.

Insider Activity

In related news, SVP David Ryan Purdue sold 5,230 shares of the firm's stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the transaction, the senior vice president owned 2,654 shares of the company's stock, valued at $619,868.24. This trade represents a 66.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Perry C. Siatis sold 22,381 shares of the firm's stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the transaction, the executive vice president directly owned 38,137 shares of the company's stock, valued at $8,771,510. This represents a 36.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.06% of the company's stock.

Wall Street Analysts Forecast Growth

ABBV has been the topic of several research analyst reports. Morgan Stanley raised their price objective on AbbVie from $269.00 to $270.00 and gave the stock an "overweight" rating in a research note on Thursday, February 5th. The Goldman Sachs Group restated a "neutral" rating and set a $223.00 price objective on shares of AbbVie in a research note on Wednesday, January 28th. Citigroup reduced their price objective on AbbVie from $235.00 to $230.00 and set a "neutral" rating on the stock in a research note on Tuesday, January 27th. Cantor Fitzgerald dropped their target price on AbbVie from $250.00 to $240.00 and set an "overweight" rating on the stock in a research report on Wednesday, April 8th. Finally, Barclays assumed coverage on AbbVie in a research report on Thursday, February 19th. They issued an "overweight" rating and a $275.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $253.00.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Late‑breaking Phase 2 data for mirvetuximab (Elahere) in platinum‑sensitive ovarian cancer and an exclusive pain‑therapy licensing deal reinforce AbbVie’s longer‑term oncology and pain pipelines, supporting growth expectations. AbbVie Ovarian Cancer Data And Pain Deal Extend Long Term Story
• Positive Sentiment: AbbVie paid a reported upfront to secure global rights to RC148, signaling management is investing in external oncology/R&D assets to bolster future revenue streams and diversify the pipeline. RemeGen Receives US$650 Million Upfront from AbbVie for RC148 Global Rights
• Positive Sentiment: AbbVie reached a large licensing agreement with Haisco (reported near $715–$745M), which monetizes or out‑licenses assets while extending geographic reach for certain pain therapies—positive for pipeline monetization and incremental revenue potential. Pharmaceutical Executive Daily: AbbVie and Haisco Enter $745 Million Licensing Agreement
• Positive Sentiment: Early‑stage ABBV‑438 myeloma data continue to underscore AbbVie’s long‑term oncology ambitions; successful advancement would broaden oncology exposure beyond established franchises. AbbVie’s ABBV-438 Myeloma Trial: Early-Stage Bet on Long-Term Oncology Growth
• Neutral Sentiment: AbbVie remains a dividend candidate for income investors and appears in recent roundups of high‑yield healthcare names, which supports income‑oriented demand even if growth questions persist. Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
• Neutral Sentiment: Commentary on AbbVie’s progress in the weight‑loss market highlights pipeline diversification but notes the company remains behind market leaders—an incremental positive but not an immediate revenue driver. Could AbbVie Crash Lilly's Weight‑Loss Party?
• Negative Sentiment: Evercore ISI slightly lowered its price target on ABBV (to $232 from $233) while keeping an Outperform rating—an incremental analyst headwind that can pressure intraday sentiment despite the small magnitude. Evercore ISI Tweaks AbbVie (ABBV) Estimates, Lowers Price Target Marginally

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.